Tumor budding predicts response to anti-EGFR therapies in metastatic colorectal cancer patients

doi:10.3748/wjg.v16.i38.4823

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 38

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5023)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-3) series.

Item

Count

PDF

427

HTML

4116

Figures (1-3)

273

Tables (1-3)

207

Sum=5023

Oct 14, 2010 (publication date) through Nov 20, 2024

Times Cited of This Article

Times Cited (40)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Oct 14, 2010; 16(38): 4823-4831
Published online Oct 14, 2010. doi: 10.3748/wjg.v16.i38.4823

Table 3 Tumor budding and K-RAS followed by PTEN, epidermal growth factor receptor, B-RAF and PIK3CA stratified by response group

Response	K-RAS	Tumor budding	PTEN	EGFR (AMP/CNG)	B-RAF	PIK3CA
NR	WT	Low	NEG	Yes	WT	WT
NR	WT	Low	NEG	Yes	WT	WT
NR	WT	Low	NEG	Yes	WT	WT
NR	WT	Low	NEG	Yes	WT	WT
NR	WT	Low	NEG	Yes	MUT	WT
NR	WT	Low	POS	No	WT	WT
NR	WT	Low	POS	No	WT	WT
NR	WT	Low	POS	Yes	WT	WT
NR	WT	Low	POS	Yes	WT	WT
NR	WT	Low	POS	Yes	WT	WT
NR	WT	Low	POS	NE	MUT	WT
NR	WT	Low	POS	No	MUT	MUT
NR¹	WT	High	NEG	No	WT	WT
NR¹	WT	High	NEG	Yes	WT	WT
NR¹	WT	High	NEG	Yes	MUT	MUT
NR¹	WT	High	POS	Yes	WT	WT
NR¹	WT	High	POS	Yes	WT	WT
NR¹	WT	High	POS	Yes	WT	WT
NR¹	WT	High	POS	Yes	MUT	WT
NR¹	MUT	Low	NEG	Yes	WT	WT
NR¹	MUT	Low	POS	Yes	WT	WT
NR¹	MUT	Low	POS	Yes	WT	WT
NR¹	MUT	Low	POS	Yes	WT	WT
NR¹	MUT	Low	POS	Yes	WT	WT
NR¹	MUT	Low	POS	Yes	WT	WT
NR¹	MUT	Low	POS	Yes	WT	WT
NR¹	MUT	High	NEG	Yes	WT	WT
NR¹	MUT	High	NEG	Yes	WT	WT
NR¹	MUT	High	POS	No	WT	WT
NR¹	MUT	High	POS	Yes	WT	WT
PR¹	WT	Low	NEG	NE	WT	WT
PR¹	WT	Low	POS	NE	WT	WT
PR¹	WT	Low	POS	NE	WT	WT
PR¹	WT	Low	POS	Yes	WT	WT
PR¹	WT	Low	POS	Yes	WT	WT
PR¹	WT	Low	POS	Yes	WT	WT
PR¹	WT	Low	POS	Yes	WT	WT
PR¹	WT	Low	POS	Yes	WT	WT
PR¹	WT	Low	POS	Yes	WT	WT
PR¹	WT	Low	POS	Yes	WT	WT
PR¹	WT	Low	POS	Yes	WT	WT
PR¹	WT	Low	POS	Yes	WT	WT
PR¹	WT	Low	POS	Yes	WT	WT

¹Cases which were correctly predicted using K-RAS and tumor budding. EGFR: Epidermal growth factor receptor; AMP/CNG: Amplification or copy number gain; MUT: Mutation; NE: Not evaluable; NEG: Negative; NR: Non response; POS: Positive; PR: Partial response; WT: Wld-type.

Citation: Zlobec I, Molinari F, Martin V, Mazzucchelli L, Saletti P, Trezzi R, De Dosso S, Vlajnic T, Frattini M, Lugli A. Tumor budding predicts response to anti-EGFR therapies in metastatic colorectal cancer patients. World J Gastroenterol 2010; 16(38): 4823-4831
URL: https://www.wjgnet.com/1007-9327/full/v16/i38/4823.htm
DOI: https://dx.doi.org/10.3748/wjg.v16.i38.4823